Correction to: Bringing cell therapy to tumors: considerations for optimal CAR binder design
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCAR-T cell therapy research · RNA Interference and Gene Delivery · Virus-based gene therapy research
This is a correction to: Richard Smith, Bringing cell therapy to tumors: considerations for optimal CAR binder design, Antibody Therapeutics, Volume 6, Issue 4, October 2023, Pages 225–239, https://doi.org/10.1093/abt/tbad019
In the originally published version of this manuscript, sections with statements needful for compliance were erroneously omitted.
Sections on FUNDING, DATA AVAILABILITY, ETHICS AND CONSENT STATEMENT, and ANIMAL RESEARCH STATEMENT were removed from online html/PDF versions. These have been replaced to read:
“FUNDING
Richard Smith is an employee and shareholder of Kite, a Gilead Company.”
“DATA AVAILABILITY
This is not applicable
ETHICS AND CONSENT STATEMENT
This is not applicable
ANIMAL RESEARCH STATEMENT
This is not applicable”
These replacements have been emended in the article.